Effective treatment of benign prostatic hyperplasia (BPH) involves not only a reduction of symptom scores and the prevention of serious complications, but also an improvement in overall patient's quality of life and cost effectiveness. There is a paucity of data regarding cost effectiveness when the pharmacologic, the minimally invasive and the surgical treatments of BPH are compared. The potassium-titanyl-phosphate laser prostatectomy seems to be a safe and effective treatment option both in the short and in the long-term run. Preliminary results indicate that photoselective vaporization of the prostate is also a cost-effective method when compared to different minimally invasive treatments and to the transurethral prostatectomy.
Introduction
Benign prostatic hyperplasia (BPH) is the most common cause of urinary tract symptoms in older men and transurethral resection of the prostate (TURP) is still considered as the gold standard treatment for this condition. Despite the fact that TURP is an effective surgical intervention it might have serious side effects. 1 Therefore, several alternatives have been developed in the last two decades in order to reduce the known perioperative morbidity of TURP.
Photoselective vaporization of the prostate (PVP) utilizes high-power (80 W) potassium-titanyl-phosphate (KTP) laser to remove obstructive prostatic tissue in a hemostatic fashion. It represents the latest evolutionary development in laser prostatectomy, and the procedure involves the use of general or spinal anesthesia and is considered a minimally invasive surgical intervention. The laser energy is trapped superficially within tissue by hemoglobin, which absorbs the green beam and acts as an intracellular chromophore. As a result, the laser energy is released to cause rapid heating and immediate vaporization of the targeted tissue, and therefore creates an open cavity comparable to that created by TURP.
Many studies by now have shown that the PVP procedure has very low complication rates, sustained significant improvements in symptom scores and peak flow rates and immediate prostatic tissue removal. [2] [3] [4] [5] This laser innovation utilizes normal saline as irrigation fluid and therefore larger prostates (4100 g) can be treated as well without the risk of absorption syndrome. 6, 7 This surgical procedure can be performed in an outpatient modality with clinical outcomes similar to those of TURP with a shorter catheterization time and a greater safety profile. It has been applied as well in highrisk patients, such as those with severe cardiac or pulmonary comorbidities and in patients under anticoagulation therapy. 8 In addition, PVP results in a lower incidence of retrograde ejaculation compared to TURP.
Today the armamentarium for the alleviation of lower urinary tract symptoms (LUTS) caused by bladder outflow obstruction includes medical treatment, minimal invasive procedures, TURP and open simple prostatectomy. For a patient and his urologist to decide which option to select, important parameters that matter include efficacy, durability, complication rates, hospitalization and catheterization time and of course a cost analysis. The definition of the 'best treatment' depends on the value that an individual and the society he lives in, give to the above-mentioned parameters and therefore, it is always difficult to draw conclusions in one country and then assume that these conclusions are valid in another environment.
In this review article, we discuss the various cost analyses of BPH treatment. At the same time, we highlight the scarce information that exists concerning the cost of the PVP laser prostatectomy and the few comparisons that have been performed with other treatment options.
Cost analysis studies in general
The true cost of an intervention consists of direct costs (drugs, procedures, complications, office visits, imaging), indirect costs (lost earnings) and intangible costs (pain and suffering). Cost analysis must incorporate the cost of treatment in question as well as the cost of treatment failures from the particular treatment in question (Table 1) . 9 In general, few retrospective studies and even less prospective studies on cost effectiveness of various BPH treatment options exist. 10 One possible solution to overcome the problem is to model the clinical situation using a decision-analytic model and or a simulation model. Such models allow flexible modeling of patient populations, treatment effects and costs, and in particular, late complications and re-treatment. 10 
Overall BPH costs
Population data survey suggest that a large amount of men in the general population, including a significant proportion of men of employment age, suffer from BPH and LUTS and seek treatment for it. [11] [12] [13] [14] In 1993, BPH-related medical expenses were estimated to exceed $4 billion annually in the US. When the aging of the population and the increasing use of medical and surgical intervention was taken into consideration, these expenses were estimated as high as $26 billion annually. 15 Physician office expenditures for BPH increased by 12.4%, from 291.2 million dollars in 1992 to 327.5 million dollars in 1998. Similarly, ambulatory surgery expenditures for BPH increased by 37%, from 73.4 million dollars in 1992 to 100.3 million dollars in 1998. Emergency department expenditures for BPH also grew 25%, from 15.5 million dollars in 1992 to 19.8 million dollars in 1998. 16 In a recent review of the literature, the costs of BPH care by therapeutic modality in the USA, were presented. Overall BPH cost of care was estimated to be in between 2.3-4 billion dollars per year. The cost for watchful waiting reached 137-862 dollars per patient per year, whereas the cost for medical therapy including various a-blockers, 5 a -reductase inhibitors and phytotherapy ranged from 73 to 974 dollars per patient per year. 9 The direct cost of minimally invasive surgical therapy was 2629, 4087 and 6872 dollars for transurethral microwave therapy, transurethral needle ablation and transurethral laser prostatectomy, respectively. 9 Open prostatectomy was the most expensive treatment modality with direct cost in between 10 477 and 12 788 dollars, whereas the gold surgical standard, transurethral prostatectomy cost was estimated to be between 3874 and 8606 dollars. At the same time indirect costs for BPH treatment reached up to 500 million dollars per year. 9 
Cost differences between various BPH treatment options
Short-and long-term effectiveness and safety are well documented for various BPH treatment options. On the contrary, short-and long-term costs have been less well studied and comparisons depend on the analysis undertaken in the few studies available.
Generally, pharmaceuticals have been shown to be more cost effective in the short term (a few years) relative to surgery. 17, 18 However, surgery has been shown to be more cost effective than pharmaceuticals in the longterm because of the annual maintenance costs of oral medication. 19, 20 In the short term, minimally invasive surgical therapies such as TUMT have been shown to be less expensive and as effective or less effective than TURP. [21] [22] [23] [24] In contrast, patients choosing a treatment pathway starting with medical therapy and ending with successful TURP or open simple prostatectomy, have the highest lifetime treatment costs. 19, 25, 26 The evidence supporting these results is not of high-level since only five studies address the longterm cost consequences or cost effectiveness of various BPH treatment alternatives beyond a few years period. 17, 19, 20, 26, 27 In Europe, a novel prospective, naturalistic study, the Triumph project aims to assess the cost-effectiveness of different therapeutic options for BPH in more than 13 000 patients in seven European countries. These results certainly will inform the debate, but we still have to wait a few more years for the final conclusions. 28 Direct comparisons between surgical procedures and pharmaceuticals are uncommon. 26 The cost effectiveness of medical therapy compared with TURP was analyzed in a hypothetical cohort of 65-year-old men with moderate-to-severe BPH. The 5-year estimated costs (1999 US $) were lower with a 1 -AR antagonist therapy ($6294) compared with those for TURP ($7334). 29 Another study in which medical therapy was compared to TURP, depicted that 5.5-10 and 7-15 years will elapse before the insurance (private or public) costs associated with finasteride and terazosin therapy, respectively, will surpass those for TURP. 17 Total costs for 2 years of treatment for each of the following alternatives: watchful waiting, finasteride, ablocker, TURP, and open prostatectomy, were compared in a study conducted by the AHCPR. Surgical therapies were estimated to cost approximately five times as much as medical treatment with a-blockers and finasteride being relatively equivalent. 30 Furthermore, a study was conducted to assess levels of medical resource utilization and costs after BPH diagnosis in the US based on information from a large, Photoselective vaporization of the prostate G Alivizatos and A Skolarikos national health care claims database. Findings from this study indicate that patients with BPH are initially treated primarily through watchful waiting (WW). Although rates of surgical intervention in the year after diagnosis are low, the associated costs are substantial, approaching $11 000 in some cases. Adverse events occurred in one out of five men undergoing surgery, with costs ranging from B$150 to $1900 per event. Therefore, the early diagnosis of symptomatic BPH and the application of an effective non-invasive treatment may further reduce the need for surgical intervention, resulting in potential savings to health care payers and providers. 31 In contrast, the only study in which the long-term follow-up of the patients was taken into consideration showed that medical management was less cost-effective than TURP when initiated in patients younger than 70 years of age as a consequence of the duration required, as medical management initiated at an early age is exceedingly costly over time. 19 Regarding minimally invasive treatments for BPH, cost comparisons have been made mainly for TUMT and TURP. Outpatient TUMT has significantly lower costs than TURP ($2629 vs $4557, 1999 US $), because no hospital stay is required. In addition, cost-effectiveness data have favoured the use of TUMT over TURP. 21, 29, [32] [33] [34] In a prospective study in which patients were followed up for over a 2-year period, TUMT showed lower primary costs, lower complications but higher re-treatment costs compared with TURP. 24 On the other hand, using a Markov model, DiSantostefano et al. examined the clinical and cost consequences over a 20-year period of watchful waiting (WW), pharmacotherapy, TUMT and TURP. The model included men experiencing uncomplicated, moderate to severe BPH and measured direct medical costs, without considering direct non-medical costs, indirect costs or intangible costs. The results of the study suggested that a-blockers and TURP are cost-effective for patients with moderate and severe symptoms. For example, at 65 years of age, the cost per quality-adjusted life year (QALY) was $US16 018 for a-blockers compared with WW and $US30 204 for TUMT vs a-blockers. TURP was the most cost-effective treatment for severe symptoms ($US5824 per QALY ) vs WW. TUMT was promising for patients with moderate symptoms and for the older patients with severe symptoms. 26 Overall, TUMT appeared to be a safe, effective, and cost-effective alternative therapy to TURP in the sort term but not in the long-term.
Laser prostatectomy apart from PVP
Various types of laser treatment are currently considered as appropriate therapy for BPH. These types mainly include the neodymium: yttrium aluminum garnet (Nd:YAG), the holmium (Ho):YAG, and the potassiumtitanyl-phosphate (KTP) laser. 35 Compared with TURP, visual laser ablation (VLAP) and interstitial laser coagulation (ILC) with the Nd:YAG laser shows less improvement in symptoms, less increase in flow rates and less reduction of prostate volume and residual urine volume. These results together with the need for long-term catheterization and the high retreatment rates led to the abundance of these techniques. 36 The unique properties of the holmium laser make it a useful tool for operating on patients suffering from BPH. When prospectively and randomly compared with TURP, holmium laser vaporization/ablation (HoLAP) showed similar efficacy to the gold standard at 1 year of follow-up, less bleeding, a shorter hospital stay, and routine next day catheter removal and patient discharge. 37 Randomized studies comparing holmium resection (HoLRP) or holmium enucleation (HoLEP) of the prostate with TURP and/or open prostatectomy showed better/equal subjective (symptom scores) and objective (urodynamics) results in favor of the laser treatment. The outcome of laser treatment was found to be as durable as the one of TURP or open prostatectomy. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] The advent of the holmium laser prostatectomy led to the improvement not only of the functional outcome of BPH laser surgery but also to the reduction of the expenses required compared to TURP. Fraundorfer et al. 48 have demonstrated that HoLRP may be an attractive alternative to standard TURP in terms of both clinical outcomes and cost-effectiveness at 1 year of follow-up (total actual cost per patient NZD2012 vs NZD2663). They reported a sorter hospital stay (actual cost per patient NZD279 vs NZD558), lower nursing requirements (NZD0 vs NZD144), lower irrigant requirements (NZD82 vs NZD192), lower blood cross-matching and transfusion (NZD0 vs NSD80) and finally fewer unplanned events and unplanned clinic visits and inpatient admissions in one year after surgery (NZD6059 vs NZD14805) for the HoLRP group compared with the TURP group.
More interestingly, the authors estimated that 93 procedures per year would cover the 5-year planned payback cost and all maintenance costs of the machine. 48 In a recently published inpatient cost analysis study, the HoLEP procedure was associated with a significant hospital net cost savings (compared with open prostatectomy mean cost per patient; Euros2356 vs Euros2868). Although the cost for the operating surgical setup, the disposable and the fibers used was higher for the laser group compared to open surgery group (Euros690 vs Euros382), the significantly lower cost of hospital stay following laser prostatectomy (Euros755.2 vs Euros1530) outweighed in the final result. 49 
KTP laser prostatectomy
Wide interest in vaporizing techniques was regained with the advent of high-powered 80-W KTP laser. 50, 51 Only a limited number of peer-reviewed articles on clinical 80 W KTP laser case series have been published to date. [2] [3] [4] [5] [6] [7] [8] [51] [52] [53] [54] [55] [56] From these studies, only three have prospectively compared the results of the KTP laser prostatectomy to those of TURP or other treatment modalities. [54] [55] [56] Furthermore, long term results of a 5-year follow-up have been presented in only one study. 2 All these studies showed that KTP laser prostatectomy is a method of high effectiveness, providing the patients with an excellent short and long-term functional outcome, whereas at the same time the method has a low morbidity.
When compared to the TURP, the improvement in micturition was shown to be similar, and when morbidPhotoselective vaporization of the prostate G Alivizatos and A Skolarikos ity was measured, the comparison was favorable to PVP, mainly owing to significantly shorter duration of catheterization and hospital stay. 54, 55 Furthermore, a recent review of the KTP series depicted similar rates of recatheterization, dysuria, urinary tract infection, incontinence, urethral strictures, and bladder neck contractures to TURP and HoLEP. 36 A comparison among 105 men treated with TURP or high-powered KTP laser showed similar financial costs for the two treatments during hospital stay in Switzerland. Costs for operation room were significantly higher for TURP (1639 vs 1226 Swiss francs (Sfr)). Costs for disposable material (including laser fibre) were significantly higher for PVP (1775 vs 222 Sfr). Costs for postoperative nursing (including postoperative irrigation solution) were less for PVP (3067 vs 3547 Sfr). 57 In another study from Australia, despite the high cost of the equipment and disposables, the KTP laser operation when performed as a day-case procedure was less expensive compared with TURP (AU$ 3368 vs AU$ 4291). This was mainly owing to much sorter hospital stay, length of catheterization and complication rates. 54 Recently, the clinical outcomes and the cost characteristics of PVP, microwave thermotherapy, transurethral needle ablation, interstitial laser coagulation and transurethral prostatectomy were compared in a decision analytic Markov model. In the model, the patients were followed for 2 years following the initial intervention. The model included costs of initial treatment, follow-up care, adverse events and re-treatment. 56 Photoselective vaporization resulted in the largest beneficial changes in IPSS score, maximum flow rates and quality of life scores at all time points evaluated, followed by transurethral resection and then interstitial laser coagulation. The largest difference between PVP and TURP was observed for Qmax (% decrease from baseline at 24 months: 221 vs 89%)
The expected cost per patient at all three time points was lowest for PVP ($3020 at 6 months; $3214 at 12 months; $3589 at 24 months) followed by ILC ($3573 at 6 months; $3965 at 12 months; $4754 at 24 months) and then TURP ($4030 at 6 months; $4331 at 12 months; $4927 at 24 months). The cost savings of the PVP stemmed from the rates of adverse events and re-treatment, which were lower that in the other procedures. Most costs at all time periods were due to the initial procedural intervention, whereas only 6-30% of the total cost was related to treatment of adverse events or to re-treatment. 56 Sensitivity analysis of the model depicted that in order for the cost of the PVP to be equal to the cost of TURP, the re-treatment rate for the PVP procedure should be 17%. This rate is more than three times greater than the PVP re-treatment rate reported in the literature. 53 The model also showed than even with rates of adverse effects for the PVP laser at the maximum observed values, the expected cost of the method at 12 and 24 months would still be less than that of all other treatment modalities. 56 Although a direct comparison between the KTP laser and the holmium laser has not yet been performed, several issues regarding cost similarities or differences can be discussed. 58 In general KTP, HoLEP and HoLAP can be performed as day-cases, especially when treating small or moderate sized prostates. The cost effectiveness of all techniques depends very much on the different reimbursement systems in different countries and, therefore, it is difficult to draw general conclusions that are applicable to every country.
Conclusion
Long-term prospective studies are necessary to gain insight into the most cost-effective treatment for different patient groups. Several aspects apart from clinical efficacy and quality of life improvement should be taken into consideration when the cost of a specific treatment is calculated. These aspects include the treatment failure rates and the need for re-treatment, the need to treat complications related to initial treatment and the need to treat specific adverse effects.
KTP laser prostatectomy seems to be an effective minimally invasive treatment option for patients with moderate to severe BPH symptoms. Preliminary costanalysis studies on KTP laser prostatectomy are in favor of the PVP vaporization when compared to transurethral prostatectomy. Furthermore, the day case KTP laser prostatectomy seems to be less expensive than other minimally invasive treatments such as microwave thermotherapy and interstitial laser coagulation. Longterm efficacy and cost effectiveness of the KTP laser prostatectomy should be further compared to pharmaceutical therapy, other forms of minimally invasive treatments such as the Holmium laser prostatectomy and finally to the gold standard of surgical therapy, the transurethral prostatectomy.
